An observational multicentre retrospective analysis of 404 patients with chronic lymphocytic leukaemia was undertaken to determine which patients gain the maximum benefit from first-line FCR (fludarabine, cyclophosphamide, rituximab). Patients (28%) who carried mutated IGHV but neither 11q nor 17p deletion were considered to be low risk. Of these low-risk patients, 71% continued to be free of disease progression following treatment and the risk of relapse decreased after four years after receiving FCR.

Read more here.


Global Database

Information by country, region and/or subtype on treatments, clinical trials and incidence/mortality rates.

Resource Library

Over 2,000 pieces of information on lymphoma diagnosis, treatment, research, support and lifestyle.

logo europe




The information on this website is for general use only. Please consult your physician if you think you may have lymphoma or
require more detailed information on the best course of treatment for you.

Our website does not host any form of advertisement. Last updated: 02/19/19. Copyright © 2018 Lymphoma Coalition. All rights reserved.